PRECISION MEDICINE: Human Longevity, Merck KGaA Form Cancer Biomarker Partnership

Jun 15, 2017 | Staff Reporter

NEW YORK (GenomeWeb) – Human Longevity (HLI) announced today that it has partnered with Germany’s Merck KGaA to identify treatment-response biomarker signatures in patients with advanced melanoma. In a pilot project, the companies will look for these biomarkers in patients with locally advanced or metastatic NRAS-mutated cutaneous melanoma who preferentially respond to Merck’s MEK1/2 inhibitor pimasertib. As part of the effort, HLI said it will generate genomic sequencing data from clinical trial participants’ tumors and germline DNA, then use its machine learning and analytical technologies to analyze the data in the context of survival and other clinical data.

RELATED STORY | CONCIERGE MEDICINE TODAY

HEALTH DECISION SUPPORT TOOLS, 2017-2018 – New Collaboration Between CMT & MPIRICA … Offers Over One Million Surgeon Quality Scores, An Industry First — Read Full Press Release Here >

 

READ FULL STORY …

SOURCE: https://www.genomeweb.com/cancer/human-longevity-merck-kgaa-form-cancer-biomarker-partnership

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: